Venkat Ramanan has served as Chief Financial Officer of Immatics since October 2025 and brings more than 25 years of experience in finance, strategy and operations across the biopharmaceutical industry.

filing / Mar 5, 2026 / receipt

Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the year covered by this Annual Report on Form 20-F and our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of December 31, 2025.

filing / Mar 5, 2026 / receipt

• Our proprietary manufacturing process is designed to expand and engineer PRAME-specific TCR T cells with a turnaround time of ~2 weeks (7-8 days, followed by 7-days of QC release testing) at 95% manufacturing success rate 12 , enabling rapid, reliable patient delivery while supporting cost efficiency and operational scalability

filing / Mar 5, 2026 / receipt

We believe our in-house manufacturing and in-house QC testing enable us to better control the manufacturing process, shorten the turnaround time, ensure high manufacturing success rate and quality of the product, and to realize potential cost efficiencies, including manufacturing capacity optimization through scalability to deliver a competitive and profitable commercial cell therapy product.

filing / Mar 5, 2026 / receipt

Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.

filing / Mar 5, 2026 / receipt

This increase resulted from our headcount growth due to our increased research and development activities including clinical trials.

filing / Mar 5, 2026 / receipt

Amie Krause | 53 | Chief People Officer

filing / Mar 5, 2026 / receipt

Jordan Silverstein | 46 | Head of Strategy

filing / Mar 5, 2026 / receipt

Peter Chambré | 70 | July 1, 2020 - Present | 2028 | Non-executive director and Chair

filing / Mar 5, 2026 / receipt

Michael G. Atieh | 72 | July 1, 2020 - Present | 2027 | Non-executive director

filing / Mar 5, 2026 / receipt

Paul R. Carter | 65 | July 1, 2020 - Present | 2027 | Non-executive director

filing / Mar 5, 2026 / receipt

Heather L. Mason | 65 | July 1, 2020 - Present | 2028 | Non-executive director

filing / Mar 5, 2026 / receipt